期刊文献+

HIV-1储存库激活剂体外激活效应研究 被引量:1

Reactivation efficacies of HIV-1 latency reversing agents in vitro
原文传递
导出
摘要 目的探讨人类免疫缺陷病毒-1(HIV-1)储存库激活剂的体外激活效应,为临床应用提供参考。方法分离得到健康供血者外周血中的CD4^+T细胞,构建HIV-1潜伏感染的原代细胞模型。用不同浓度(0.5、1、2μmol/L)的帕比司他(Panobinostat)、伏立诺他(SAHA)(Vorinostat)、BIX-01294、JQ-1、Bryostatin-1、GS-9620、地西他滨(Decitabine)、戒酒硫(Disulfiram)、Sirolimus分别处理细胞,在不同作用时间(1、3、5 d)后利用流式细胞分析仪检测每种药物对HIV-1储存库细胞的绿色荧光蛋白(GFP)表达效率及细胞存活率,并确定每种激活剂的最佳激活浓度和作用时间。结果通过对由HIV-1启动子驱动的GFP表达效率及细胞存活率的统计分析,明确了在该细胞模型中这9种HIV-1储存库激活剂的最佳作用浓度和作用时间:Panobinostat的最佳激活浓度为1μmol/L,最佳作用时间为3 d;SAHA的最佳激活浓度为2μmol/L,最佳作用时间为1 d;JQ-1、Bryostatin-1和GS-9620在该模型中的最佳激活浓度均为1μmol/L且最佳作用时间均为1 d;BIX-01294、Decitabine、Disulfiram、Sirolimus在该模型中的最佳激活浓度均为0.5μmol/L且最佳作用时间均为1 d。横向对比发现,浓度为1μmol/L,作用时间为3 d的Panobinostat与浓度为0.5μmol/L,作用时间为1 d的Sirolimus在这9种药物中的激活效率最高,且对细胞存活无明显影响。结论系统比较确认了9种病毒储存库激活药物在体外细胞模型中的激活效率,及最佳作用浓度和时间,为后续这些药物的临床实验研究提供重要参考。 Objective In order to systematically compare the reactivation effects of human immunodeficiency virus-1(HIV-1)latency reversing agents in vitro,and provide reference for clinical application.Methods CD4^+T cells from peripheral blood of healthy donors were isolated to construct the primary cell model of HIV-1 latency.Different concentrations(0.5,1,2μmol/L)and different time of action(1,3,5 day)of panobinostat,SAHA,BIX-01294,JQ-1,bryostatin-1,GS-9620,decitabine,disulfiram and sirolimus were tested;flow cytometry was used to determine the GFP activation efficiency and cell survival of HIV-1 latency cells.Results Through the statistical analysis of GFP expression driven by HIV-1 promoter and cell survival,optimal concentration and time of action of 9 HIV-1 latency reversing agents in this cell model were determined:the optimal activation concentration of panobinostat was 1μmol/L,and the optimal activation time was 3 days.The optimum activation concentration of SAHA was 2μmol/L,and the optimum reaction time was 1 day.The optimal activation concentrations of JQ-1,Bryostatin-1 and GS-9620 in the model were 1μmol/L and the optimal time was 1 day.The optimal activation concentrations of BIX-01294,Decitabine,Disulfiram and Sirolimus in the model were 0.5μmol/L and the optimal reaction time was 1 day.Statistical analysis showed that panobinostat with a concentration of 1μmol/L for 3 days and sirolimus with a concentration of 0.5μmol/L for 1 day had the highest reactivation efficacy among the 9 drugs,with no significant effect on cell survival.Conclusion Reactivation efficacies,optimal concentrations and time of action were determined for 9 latency reversing agents,which provides important references for future clinical applications of these drugs.
作者 黄卓琼 赵露 邓凯 龚逸鸿 HUANG Zhuo-qiong;ZHAO Lu;DENG Kai;GONG Yi-hong(School of Biomedical Engineering,Sun Yat-sen University,Guangzhou,Guangdong 510080;Zhongshan School of Medicine,Sun Yat-sen University,Guangzhou,Guangdong 510080,China)
出处 《热带医学杂志》 CAS 2019年第10期1191-1196,1208,共7页 Journal of Tropical Medicine
基金 广东省自然科学基金(2016A030313325).
关键词 HIV-1 潜伏感染 病毒储存库 储存库激活剂 HIV-1 Latent infection Viral latent reservoir Latency reversing agents
  • 相关文献

参考文献1

二级参考文献35

  • 1Walensky RP, Paltiel AD, Eosina E, et al. The survivalbenefits of AIDS treatment in the United States [ J ]. J Infect Dis, 2006, 194(1): 11-19.
  • 2Natarajan V, Bosche M, Metcalf JA, et al. HIV-1 replication in patients with undetectable plttsm a virus receiving HAART. Highly active antiretroi'tal therapy [J]. Lancet, 1999, 353 (9147) : 119-120.
  • 3Blankson JN, Persaud D, Siliciano RF. The ehttl!enge of viral reservoirs in HIV-1 infection [J]. Annu Rev Med, 2002, 53 ( 1 ) :557-593.
  • 4Carter CC, Onafuwa-Nuga A, MeNamara LA, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs [J]. Nat Med, 2010, 16 (4) : 446-451.
  • 5Rasmussen TA, Tolstrup M, Winckelmann A, et al. Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials[J]. Hum Vaccin Immunoter, 2013, 9(4) : 790-799.
  • 6Sedaghat AR, Siliciano JD, Brennan TP, et al. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patiens on HAART [ J ]. PLoS Pathog, 2007, 3 (8) : e122.
  • 7Chun TW, Nickle DC, Just ement JS, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiret roviral therapy [J]. J Infect Dis, 2008, 197(5): 714-720.
  • 8Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy [J]. Nat Med, 1999, 5(5): 512-517.
  • 9Persaud D, Pierson T , Ruff C, et al. A stable latent reservoir for HIV-1 in resting CD4+ T lymphocytes ininfect-ed children [J]. J Clin Invest, 2000, 105(7): 995-1003.
  • 10Persaud D, Gay H, Ziemniak C, et al. Functional HIV cure after very early ART of an infected infant [C]. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, USA, 2013- 3-3.

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部